Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And what if it “passes” the test during human clinical trials?
How far does the PPS go up from there?
$10.00 perhaps?
I’m guessing approval sends us to at least $2.00+ before a pullback to closer to $1.25 or $1.50
$5.00 might be stretching it, but anything is possible.
A run of 30x from FDA approval would take us to about $2.10
We would need a run of about 70x to get to near $5.00
Yeah, might not get it until Monday
And if $0.29 is their EPS
Net Profit = $5 million
O/S = 17.2 million shares
EPS = $5 million / 17.2 million
EPS = $0.29 per share
P/E industry average is 39x in this industry, as Stervc has stated many times.
$0.29 * 39 = $11.31 per share
I can see a run to about $6.00 - $8.00 range, with audited financials, if Net Profit is at least $4 million, and total revenue is well over $100 million audited for 2022.
Yep, and if any one is selling ….
They would need to have their head examined.
We’re about to get 2022 audited financials (any day now).
Thoughts? ….
Yeah, I have one.
Short squeeze is coming.
Yep ….
Well said.
Correct ….
Their Total Assets are worth more than their Total Liabilities.
Same here
This has always been a wait and hold. Long-term.
You do realize ….
“Total Liabilities and Stockholders Deficit” must equal the same exact dollar amount as “Total Assets”
If a company had $500 million in “Total Assets” than “Total Liabilities and Stockholders Deficit” would also equal a total of $500 million (the same exact amount).
This filing for GRPS shows:
Total Assets = $7,831,040
Total Liabilities and Stockholders Deficit = $7,831,040
Same exact amount.
At least their finance/accounting person did it correctly.
That dollar amount you portrayed doesn’t help or hurt the stock.
Samson please ….
C’mon yo.
That’s in addition to the $125 million annual revenue they did in 2022.
So add another $2 million “per month” (or $24 million) for 2023.
Also, the $15 million annual revs from the recent Karr acquisition would also need to be added.
$125 million
+ $24 million (Savannah)
+ $15 million (Karr acquisition)
= $164 million (projected 2023 revenue)
Very true ….
And as a result, the PPS could jump to $0.45 on IDE submission in the 1st half of May, and launch up to $2.50 on approval from the FDA by late May / early June.
So we could see the PPS skyrocket over the next 8-10 weeks.
Predictions for PPS ???
IDE submission (PPS ?)
FDA approval (PPS ?)
Human Trials (PPS ?)
Full approval and going to market to be used on everyday humans going forward (PPS ?)
Yeah, they’ve been walking it down.
Yep, ATTENTION EVERYONE
Promotion badge has been removed.
It was up for less than 24 hours.
It will probably run big ….
After all of Samsung’s low bids finally get filled, lol.
I doubt they would lie about their financials in a PR
In their most important PR so far, they said they were a profitable company and that their 2022 financials were better than 2021, in this PR below.
Here is Tim Evans quote:
“Tradition is a profitable company with an established customer base. Tradition surpassed our 2021 audited numbers by a significant margin. I’ll be talking more about this soon once our 2022 audit is complete. Suffice it to say we are growing and now through this acquisition we have a rock-solid foundation that will carry us far into the future.”
From the link below ….
https://finance.yahoo.com/news/aqua-power-systems-inc-wholly-183000958.html
15 days appears to be the standard.
Per OTC Markets.
But there can always be exceptions to that rule, just like you pointed out.
Let’s hope they find a way to get it removed sooner than the 15 days.
Be careful, it’s commonly assumed that most people who naked short stocks, interject themselves in to the conversation online to help facilitate their motive.
Just looking out for you.
So you guys are working “together” here then?
Good to know.
Wait, you just said “we’ve” been spitting facts the last month ….
Who is “we” ???
Correct, I have seen some “shell” companies in the past that get slapped with a promotion badge, they ended up CE or on the expert market, etc. But I wouldn’t say it’s most, now that I think of it.
But you made a good point, this is no longer a shell company.
Also, in researching OTC Markets, the badge looks like it will stay for 15 days.
LOL ….
The 2021 and 2020 financials were audited.
Try again.
I agree ….
I’m still bullish here, but they certainly need to be on this, and get this resolved.
I don’t believe they can uplist to OTCQB now.
Not with this badge lurking over them.
Now, if the badge ever gets removed, then yeah, OTCQB would still be possible.
Most companies who get this badge eventually go CE (caveat emptor). We have to hope this won’t happen to APSI. It just wouldn’t make sense, with their $100+ million in “audited” revenue. Why would they lie about that?
Hopefully all this gets sorted out.
But this is a blemish now, and hopefully they do what is needed to get this stupid badge removed.
This PR from the horse’s mouth says otherwise.
So, your statement isn’t quite correct.
https://newsdirect.com/news/aqua-power-systems-takes-aggressive-action-to-combat-suspected-illegal-naked-short-selling-272923592
Just had a “Truck” deliver me a new electronic, even though it didn’t say APSI on the truck.
Now I can throw the old dusty Samsung away, since it kept putting out crappy noise and hissing sounds, as it was just trying to scare people with its gibberish.
And Tim Evans even said that revenue was higher in 2022 than in 2021, and that they were profitable in 2022. He said that in one of the PR’s.
We’ve never seen anything like it in the OTC
- $125 million (annual revenue)
- Profitability ($4.5 million Net profit)
- Even after using capital to grow the business and acquire other companies with multiple acquisitions.
- Only 17.2 million outstanding shares.
- And access any time they want to $10 million in finding, that they can tap in to, as the share price grows in value.
Name another OTC company that has ever had this kind of revenue, profitability, aggressive growth and expansion strategy through acquiring other companies, and very low O/S, plus $10 million in funding as they grow over the next two years that is not toxic at all for shareholders.
You can’t find a better opportunity than this one in the OTC.
I’m going to make a bold prediction.
One day this company will be on the NYSE. Several years after being on the Nasdaq.
Excellent ….
Close to $24 million in revenue projected in 2025. With over $7 million of profit. Huge net profit margin.
I’ll gladly take $3.00 per share
For my 2 million shares.
And I will always hold some shares forever (maybe 10% of my current shares), because I want to stay a proud shareholder of such a great technology that will save people’s lives.
Sounds good ….
Do you still have all your 20+ million shares?
Hope you make many $millions here.
It sure is ….
That $24 million (addition alone), at 2x revenue would = $48 million market cap for just that.
And $48 million / 17 million O/S
= nearly $3.00 per share
Just from that $24 million addition in Savannah alone. That doesn’t even factor in the other $125 million revenue they’re already making, lol.
So much growth to come here.
Yeah, like TSNP (Humbl)
What a shed-hole that turned out to be. I did make a small amount in it in early 2021.
APSI = $125 million revenue and growing.
TSNP = zero revenue.
Lots of accumulation today ….
We probably won’t see another trade below $0.0041 for the rest of the day.